Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Daniel M. Hartung, PharmD, MPH
Advertisement
Articles by Daniel M. Hartung, PharmD, MPH
Little is known about opioid prescribing patterns in patients with chronic overlapping pain conditions. This study suggests target populations for interventions to manage chronic pain.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
ATTR-CM Incidence, Prevalence Rose Sharply in the US
2
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
3
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
4
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
5